ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31
Zomedica Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.08−0.00 (-0.55%)
Close on Oct 19, 2026
- Market cap
- $77.40M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.0165 (+26.40%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Zomedica Corp. grew revenue 30.1% to $36.88M over the twelve months to Jun 30, 2026. Free cash flow was -$13.67M.
Revenue
$36.88M
+30.1% vs. a year earlier
Operating income
-$20.75M
TTM Q2 2026
Free cash flow
-$13.67M
TTM Q2 2026
EPS, diluted
-$0.01
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $77.40M
- P/E ratio
- –
- Price to sales
- 2.10
- Price to book
- 0.72
- Dividend yield
- –
- Free cash flow yield
- -17.66%
Fundamentals
- Revenue
- $36.88M
- Net income
- -$18.95M
- EPS, diluted
- -$0.01
- Free cash flow
- -$13.67M
- Book value per share
- $0.11
- Diluted shares
- 980M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$36.88M+30.1% YoY
Gross profit
$24.13M+22.6% YoY
Operating income
-$20.75M
Net income
-$18.95M
EPS, diluted
-$0.01
Free cash flow
-$13.67M
Reported periodTrailing twelve months